cambridge, massachusetts, December 18, 2024 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced: kate havillandThe CEO will present the company profile and 2025 outlook at the 43rd JPMorgan Healthcare Annual Conference in December 2020. Monday, January 13, 2025in 9am Pacific Time (12:00 PM (Eastern Standard Time)).
A live webcast of the presentation can be viewed by visiting the Investors and Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on the Blueprint Medicines website for 30 days after the presentation.
About Blueprint Medicine
Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines. We aim to alleviate human suffering by solving important medical problems in two core areas: Allergy/Inflammation and Oncology/Hematology. Our approach begins by targeting the root causes of disease, leveraging deep scientific knowledge in our core areas of focus and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib), which we offer to patients with systemic mastocytosis (SM) in the United States. Europe. Leveraging our established research, development, and commercial capabilities and infrastructure, we currently have a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases such as SM, chronic urticaria, and breast cancer. By promoting this, we aim to significantly expand our influence. Solid tumor. For more information, please visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
trademark
Blueprint Medicines, AYVAKIT, AYVAKYT, and related logos are trademarks of Blueprint Medicines Corporation.
SOURCE Blueprint Medicines Corporation
